Journey Medical Corp

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for dermatological conditions. The company's current portfolio includes eight FDA-approved prescription drugs for dermatological conditions, all marketed in the U.S. Journey Medical Corporation acquires product rights and candidates by licensing or acquiring ownership interests, funding research and development, and then commercializing these products through its field sales organization. It operates as a controlled subsidiary of Fortress Biotech, Inc. On November 1, 2024, the FDA approved Emrosi for treating inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories, Ltd. Initial supply of Emrosi became available in March 2025, and sales promotion began in April 2025. Journey Medical Corporation is commercializing Emrosi in the U.S. using its existing commercial team. Effective after the close of U.S. equity markets on June 27, 2025, the company joined the small cap Russell 2000® Index and the broad-market Russell 3000® Index as part of the 2025 annual Russell Index reconstitution. Journey Medical Corporation was incorporated in Delaware in 2014.